Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Isis Pharma Inks RNA Deal With J&J
by Ann M. Thayer
January 12, 2015
| A version of this story appeared in
Volume 93, Issue 2
Isis Pharmaceuticals will work with Janssen Biotech, part of Johnson & Johnson, to develop RNA-targeted drugs against autoimmune disorders of the gastrointestinal tract. Janssen has expertise in formulating drugs that can be delivered to targets in the gut. J&J will pay Isis $35 million up front. The agreement covers three programs for which Isis could receive another $800 million in license fees and milestone payments. If Janssen licenses promising drug candidates, it will handle the development, regulatory, and commercialization aspects.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter